Read more about the requirements for taking part in joint testing on the Kanta Services website:
Situation of the Prescription service
The situation of the joint testing of the Prescription service is compiled on this page. Tabulating starts from joint tests completed on 29 April 2016.
Situation of the Prescription service
Open allOngoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20102016 / 30.12.2016 |
| Functionality for action on behalf of a minor |
20072020 / 14.9.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20122022 / 8.2.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20012016 / 30.11.2016 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 17.2.2020 |
| Functionality for action on behalf of a minor | 20072021 / 14.9.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20032022 / 3.2.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20062016 / 27.12.2016 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 14.9.2020 |
| Functionality for action on behalf of a minor | 20062021 / 30.6.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 27.4.2022 / 20162022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20142017 / 14.3.2017 |
| Functionality for action on behalf of a minor | 20032021 / 4.5.2021 |
| Refusal to share prescription information | 20052021 / 29.6.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 29.4.2022 / 20172022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
Prescription's MR and CDA R2 specifications 4.00 and requirement specifications 3.00 (DynamicHealth eResepti Interface) |
18.5.2022 | Ongoing, 3.6.2022 | Not started | Not tested |
| The 2022 version of the Pharmaceutical Database | 11.7.2022 | Ongoing, 14.7.2022 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20032016 / 30.12.2016
|
| Forward compatibility of the functionality to act on behalf of a minor |
- / 12.3.2020 |
| Functionality for action on behalf of a minor |
20122020 / 20.11.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20022022 / 2.2.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20032016 / 9.12.2016 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
The 2022 version of the Pharmaceutical Database |
14.9.2022 | Not started | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information |
20022018 / 5.10.2018 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 7.9.2020 |
| Functionality for action on behalf of a minor | 2.5.2022 / 20192022 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (Prescription's HL7 specifications 3.42) | 29.4.2022 / 20182022 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (Prescription's HL7 specifications 3.63) | 5.5.2022 / 20212022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20092016 / 29.12.2016 |
| Functionality for action on behalf of a minor |
20032020 / 16.3.2020 |
| Functionality for action on behalf of a minor (testing of system changes) |
20052020 / 10.8.2020 |
| The 2022 version of the Pharmaceutical Database | 20102022 / 11.4.2022 |
| Structured dosage | 20112022 / 12.4.2022 |
| FHIR interface to search for identifiers | 20082022 / 22.3.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20022016 / 9.12.2016 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 7.5.2020 |
| Functionality for action on behalf of a minor | 20012022 / 31.1.2022 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20132022 / 11.4.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
- / 25.11.2016 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 6.2.2020 |
| Functionality for action on behalf of a minor |
20082020 / 22.9.2020 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20082016 / 30.12.2016 |
| Refusal to share prescription information |
20012018 / 11.1.2018 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 16.4.2020 |
| Functionality for action on behalf of a minor | 20022021 / 12.4.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 26.4.2022 / 20152022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
The 2022 version of the Pharmaceutical Database |
26.8.2022 | Ongoing, 2.9.2022 | Not tested | Not tested |
| Structured dosage | 24.8.2022 | Ongoing, 2.9.2022 | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20042016 / 13.12.2016 |
| Refusal to share prescription information |
20202017 / 1.6.2017 |
| Functionality for action on behalf of a minor |
20012020 / 14.1.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20042022 / 3.2.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20192017 / 11.5.2017 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 14.2.2020 |
| Functionality for action on behalf of a minor | 18.11.2021 / 20102021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20062022 / 23.2.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20122017 / 11.1.2017 |
| Cross-border prescription |
20012019 / 30.9.2019 |
| Functionality for action on behalf of a minor |
20062020 / 8.9.2020 |
| The 2022 version of the Pharmaceutical Database | 20252022 / 29.4.22 |
| Structured dosage | 20262022 / 29.4.22 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
|
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20072016 / 30.12.2016 |
| Refusal to share prescription information |
20212017 / 5.6.2017 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 5.5.2020
|
| Functionality for action on behalf of a minor |
20042020 / 8.10.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 17.2.2022 / 20072022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
Prescription's MR and CDA R2 specifications 3.63 and requirement specifications 2.9 |
23.9.2020 | Ongoing, 17.11.2020 | Not tested | Ongoing, 13.9.2022 |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 |
20132016 / 30.12.2016 |
| Refusal to share prescription information |
20222017 / 4.12.2017 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 8.5.2020 |
| Functionality for action on behalf of a minor |
20132020 / 26.11.2020 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 22.3.2022 / 20092022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0 |
25.8.2022 | Not started | Not started | Not started |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20172017 / 27.1.2017 |
|
Cross-border prescription |
20022020 / 20.2.2020 |
| Functionality for action on behalf of a minor |
20102020 / 24.9.2020 |
| Structured dosage | 3.5.2022 / 20242022 |
| The 2022 version of the Pharmaceutical Database | 3.5.2022 / 20232022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
The 2022 version of the Pharmaceutical Database |
19.9.2022 | Not started | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20052016 / 20.12.2016 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 8.4.2020 |
| Functionality for action on behalf of a minor (OMNI360 Kertomus) |
20012021 / 21.1.2021 |
| Functionality for action on behalf of a minor | 20082021 / 14.9.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database (OMNI360 Kertomus) | 20122021 / 18.11.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20052022 / 24.2.2022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
Prescription's MR and CDA R2 specifications 4.0 and requirement specifications 3.0 |
20.9.2022 | Not started | Not started | Not started |
Ongoing joint testings
No ongoing joint testings
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20162017 / 27.1.2017 |
| Cross-border prescription |
20022019 / 10.12.2019 |
| Functionality for action on behalf of a minor |
20092020 / 24.9.2020 |
| Structured dosage | 3.5.2022 / 20222022 |
| The 2022 version of the Pharmaceutical Database | 3.5.2022 / 20202022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
The 2022 version of the Pharmaceutical Database |
16.9.2022 | Not started | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
- / 22.11.2016 |
| Forward compatibility of the functionality to act on behalf of a minor |
- / 10.9.2020 |
| Functionality for action on behalf of a minor | 20092021 / 11.10.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 8.4.2022 / 20142022 |
| Ongoing joint testings | Registration, return date of pre-test cases | Testing between system supplier and Kela | Testing between client test organisation and Kela | Cross-testing |
|---|---|---|---|---|
|
The 2022 version of the Pharmaceutical Database |
15.9.2022 | Not started | Not tested | Not tested |
| Accepted joint testings | Statement number and date |
|---|---|
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information |
20152017 / 11.1.2017
|
| Forward compatibility of the functionality to act on behalf of a minor |
- / 14.1.2020 |
| Functionality for action on behalf of a minor | 20042021 / 16.6.2021 |
| Forward compatibility of the structured dosage and the 2022 version of the Pharmaceutical Database | 20112021 / 18.11.2021 |